They Labeled It Sterile. It Had Fungus In It.

Case No. 1:25-cv-00574  |  Filed February 20, 2025  |  U.S. District Court, District of Colorado  |  Defendant: Alcon Laboratories Inc.

The Non-Financial Ledger

Kathy Even lives in Aurora, Colorado. She bought a box of eye drops because her eyes were dry and burning. The product said “STERILE” on the label. She believed it. That is the entire premise of this story: a person trusting a corporation’s word about something they were putting directly into their eyes, twice, or more, as needed, for months.

She used the product as she was told. One or two drops in the affected eye, as needed. She did that, repeatedly, while inside at least one of those sealed single-use vials, something was growing that had no business being there. She did not know. Alcon knew the risks that came with manufacturing ophthalmic products. She did not. She paid a name-brand premium specifically because she believed Systane was the kind of company that got the sterile part right.

When the recall finally came, it arrived on Christmas Eve. The notice told her to stop using the product immediately. It mentioned that the contamination was “fungal in nature.” It did not tell her what specific fungus had been sealed inside the vials she had already used. Alcon’s public recall statement, to this day, does not name the organism. Kathy Even is left to live with the uncertainty of what exactly she placed in her eyes and whether there are long-term consequences she cannot yet see.

The recall notice did not directly offer her a refund. As of February 20, 2025, the date this lawsuit was filed, she had received nothing back. She had already paid the price premium. She had already used the product. She had already gone to the eye doctor, a visit she would not have needed had the vials contained what the label promised. Her symptoms: red eyes, ocular swelling and itching, and discharge. These are not abstract harms quantified in a spreadsheet. These are the daily, physical consequences of a corporation’s failure to maintain a sterile manufacturing environment for a product designed to go into human eyes.

The lawsuit states she fears future injury from prior use of the product. That sentence is worth sitting with. She does not know if she is done experiencing consequences. Neither does anyone else who used Lot 10101. Alcon reported no adverse events at the time of recall, but that does not mean there were none. It means none had been formally reported to them yet.

This is the thing that does not show up in settlement math: the months of use before the recall, the Christmas Eve notification, the refund that never came, the doctor visit that cost money and time, and the open question of what exactly was growing in those vials and what it may have done. Alcon collected the premium price. Kathy Even collected the symptoms.

Legal Receipts: What the Documents Actually Say

Every quote below comes verbatim from Case No. 1:25-cv-00574, filed February 20, 2025, in the U.S. District Court for the District of Colorado. Nothing here is paraphrased.

“Alcon Laboratories is voluntarily recalling one (1) lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101) to the consumer level. Alcon evaluated a consumer complaint of foreign material observed inside a sealed single use vial and determined the material to be fungal in nature.”

— Alcon Recall Statement, December 21, 2024

• This is Alcon’s own language. The recall was triggered by a consumer complaint, meaning a member of the public had to notice visible foreign material in a sealed sterile product before Alcon acted. There is no indication in the source document that Alcon’s internal quality control caught the problem first.
• Alcon identified the material as “fungal in nature” but refused to specify the organism. Consumers who used the product were not told what pathogen they may have been exposed to.
• The product was sealed. The fungal material was inside. This eliminates any consumer-handling explanation and places the contamination event squarely inside Alcon’s manufacturing, packaging, or storage chain.

“Risk Statement: Fungal contamination of an ophthalmic product is known to potentially cause eye infections. If an infection occurs, it may be vision-threatening, and in very rare cases potentially life-threatening in immunocompromised patients. To date, Alcon Laboratories has not received any reports of adverse events related to this recall.”

— Alcon Recall Statement, December 21, 2024

• Alcon confirms, in its own words, that this class of contamination can permanently damage vision. This is not an allegation by the plaintiff’s attorneys. This is Alcon’s risk assessment of its own product.
• The claim that no adverse events had been reported at the time of the recall announcement is not the same as confirming no harm occurred. The recall was issued the same week it became public; consumers who had been harmed may not yet have connected their symptoms to the product.
• Plaintiff Kathy Even suffered red eyes, ocular swelling, itching, and discharge, and was required to seek medical care. These are documented in the complaint filed two months after the recall.

“Defendant’s failures to timely disclose the Product’s fungal contamination amount to negligent omission, and its representations that the Product was safe, STERILE, and of acceptable quality amount to negligent misrepresentation.”

— Class Action Complaint, Para. 38, Filed February 20, 2025

• The word “STERILE” appeared on the product’s packaging as a direct claim. Colorado law and federal consumer protection standards treat label claims as express warranties. Alcon is alleged to have breached that warranty by shipping product that was demonstrably not sterile.
• The complaint argues that Alcon possessed exclusive knowledge of the conditions that could produce contamination and had a duty to disclose contamination once discovered, rather than continuing to sell and allow consumers to use the product.

“The active ingredient in the Product, Polyethylene Glycol, can serve as a carbon source for fungi.”

— Class Action Complaint, Para. 20, Filed February 20, 2025

• This is a documented biochemical fact cited in the complaint. Polyethylene Glycol is an ingredient Alcon chose. Its capacity to support fungal growth is a known property. The complaint argues this makes rigorous sterility controls even more critical, not less.
• If Alcon’s quality controls failed in an environment where the product’s own chemistry can feed fungal growth, that failure is compounded rather than excused.

“Defendant acted willfully in concealing from Plaintiff and other Class members, and not disclosing, the Product’s fungal contamination.”

— Class Action Complaint, Para. 81, Filed February 20, 2025

• The allegation of willful concealment, if proven at trial, opens Alcon to treble damages under the Colorado Consumer Protection Act (Colo. Rev. Stat. §§ 6-1-101, et seq.). This is the difference between paying back what consumers spent and paying back three times that amount plus attorneys’ fees.
• The complaint explicitly states: “Defendant engaged in bad faith conduct, entitling Plaintiff and other Class members to treble damages.” The legal standard for bad faith is a factual question the jury will determine.

The Timeline: From Sealed Vial to Federal Lawsuit

Every date below is sourced directly from the complaint. The gap between contamination discovery and consumer notification is documented; the gap between notification and actual refund remains open.

Societal Impact Mapping

Public Health

Fungal contamination in an ophthalmic product carries a documented cascade of public health consequences. The complaint, combined with Alcon’s own recall language, establishes the following harms.

• Potential for fungal eye infections in every consumer who used Lot 10101. The product was distributed nationwide to retail and internet outlets, meaning the exposed population is geographically dispersed and difficult to fully contact or monitor.
• Documented personal injuries in at least one confirmed user. Plaintiff Kathy Even developed red eyes, ocular swelling, itching, and discharge, and required medical intervention after using the product for months without knowing it was contaminated.
• Vision-threatening risk acknowledged by Alcon itself. Alcon’s own recall risk statement says fungal ocular infections “may be vision-threatening.” This risk applied to every person who used the recalled lot before the recall was announced.
• Potentially life-threatening risk for immunocompromised users. Alcon explicitly acknowledged this in its recall statement. Systane products are marketed for everyday dry-eye relief, a condition common in elderly populations and individuals on immunosuppressant medications, exactly the demographic most at risk.
• Delayed notification compounded exposure. The recall was triggered by a consumer complaint, not by Alcon’s internal monitoring. Consumers continued using the contaminated lot for an unknown period before the December 21, 2024 announcement, and Kathy Even received no individual notice until December 24, 2024.
• Alcon refused to identify the specific fungal organism to the public, meaning affected consumers and their physicians lack the information needed to guide targeted treatment or surveillance.

Economic Inequality

The financial harm in this case falls entirely on consumers while the corporation retained full payment for a product that failed to meet its own label claims.

• Consumers paid a name-brand price premium for Systane over generic alternatives. The complaint specifically notes that Kathy Even paid a premium for the Alcon Systane brand, premised on the brand’s implied promise of quality and sterility. That premium bought her fungal exposure, not protection.
• Alcon provided no direct refund mechanism in the recall notice sent to consumers. The notice instructed consumers to return the product to the place of purchase, placing the burden of navigating a refund on individuals who had already been harmed, not on the corporation that caused the harm.
• Affected consumers bore additional unreimbursed costs. Kathy Even was required to seek medical attention from an eye doctor. This cost is currently unreimbursed. For consumers without robust health insurance, a doctor visit triggered by a corporation’s manufacturing failure represents a direct out-of-pocket transfer of wealth from consumers to the healthcare system, with Alcon bearing none of it.
• The class action mechanism exists precisely because individual losses are too small to litigate alone. The complaint acknowledges that the individual damages per consumer are small relative to the cost of bringing a solo lawsuit, meaning without a class action, Alcon would face zero meaningful accountability and retain every dollar it collected from contaminated-product sales.

The “Cost of a Life” Metric

What Now? The Resistance

Alcon Laboratories Inc. is headquartered at 6201 South Freeway, Fort Worth, Texas 76134. The people and institutions with the power to act on this are identified below, followed by what you can do.

Corporate Parties Named

• Alcon Laboratories Inc., defendant, Fort Worth, Texas. Specific executive officers responsible for manufacturing quality control are not named in this complaint; the corporate entity is sued as a whole.
• Does 1 through 10: Placeholder defendants in the complaint covering additional individuals or entities whose identities may be revealed during discovery.
• Plaintiff’s counsel: Wilshire Law Firm, PLC; attorneys Thiago M. Coelho, Chumahan B. Bowen, Jennifer M. Leinbach, and Reuben A. Aguirre.

Watchlist: Regulatory Bodies With Jurisdiction

• U.S. Food and Drug Administration (FDA): Primary federal regulator for pharmaceutical manufacturing, labeling, and recall enforcement. The FDA published Alcon’s recall announcement on December 23, 2024. It has authority to investigate current Good Manufacturing Practice (cGMP) failures at Alcon’s facilities.
• Federal Trade Commission (FTC): Has jurisdiction over deceptive advertising and labeling in consumer products. The “STERILE” label claim on a product confirmed to contain fungal contamination is directly relevant to FTC’s deceptive practices authority.
• Colorado Attorney General’s Office: The Colorado Consumer Protection Act (Colo. Rev. Stat. §§ 6-1-101, et seq.) is at the center of this lawsuit. The AG’s office has independent enforcement authority under this statute and can pursue penalties separate from any class action settlement.
• U.S. Department of Justice (DOJ): If FDA investigation surfaces systemic cGMP violations or evidence of concealment from federal regulators, the DOJ has authority to bring criminal charges under the Federal Food, Drug, and Cosmetic Act.

Actions You Can Take Right Now

• Check your eye drops. If you purchased Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, check the lot number. Lot 10101 with expiration date 2025/09 is the recalled batch. Stop using it. Return it to your place of purchase for a refund.
• Report your symptoms to the FDA. If you used this product and experienced any eye irritation, redness, discharge, or pain, file a MedWatch report at fda.gov/safety/medwatch. Every report creates a documented record that regulators and courts can use.
• Contact Alcon directly at 1-800-241-5999 (Monday to Friday, 7:30am to 6:00pm Central) to demand your refund. Document the date and time of your call and what you were told. Written documentation of Alcon refusing to refund strengthens the class action record.
• If you are a member of the proposed class (a Colorado consumer who purchased Lot 10101 for personal use), monitor ClassAction.org and the case docket at U.S. District Court for the District of Colorado, Case No. 1:25-cv-00574, for class certification updates.
• Share this information with your community, especially with elderly neighbors, family members on immunosuppressants, or anyone who uses preservative-free eye drops regularly. These are the populations Alcon’s own recall identified as facing the highest risk of life-threatening complications.
• Push your local mutual aid networks and community health organizations to spread awareness in neighborhoods without easy internet access. Retail pharmacies in lower-income areas often sell name-brand products like Systane to people who cannot afford to monitor recall databases. Human-to-human notification fills the gap that corporate recall notices leave.